

# PRAXIS PRECISION MEDICINES, INC.

# Reported by **NEMIROFF ALEX**

### FORM 4

(Statement of Changes in Beneficial Ownership)

### Filed 11/21/25 for the Period Ending 11/20/25

Address 99 HIGH STREET, 30TH FLOOR

**BOSTON, MA, 02110** 

Telephone 617-300-8460

CIK 0001689548

Symbol PRAX

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31



### FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Nemiroff Al		porting Pers	son <del>*</del>	2.	Issue	r Nam	e and Tick	er o	or Tradi	ing Sym	hol	5.	Relationship	of Reno	rting Person	n(s) to Issi	ner	
	la	1. Name and Address of Reporting Person *				2. Issuer Name <b>and</b> Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	ex			Pı	axi	s Pre	cision M	[edi	icines	, Inc.	[ PRAX							
(I as				]									Director		10%	6 Owner		
(Lus	(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)								_X_ Officer (give title below) Other (specify below)  General Counsel and Secretary					
C/O PRAX	IS DDFCI	ISION					11/	20/	2025						·			
MEDICINE			CTDEE	т			11/	_0,,	2025									
30TH FLOO		77 IIIGII	SIKEE	1,														
30111 FLO	(Stre	eet)		4	IfΔn	nendm	ent, Date (	)ria	inal Fil	ed om	/DD/VVVV)	6	. Individual o	r Joint/G	roun Filing	(Check Appl	licable Line)	
	(	,		T.	пли	iiciidiii	ciii, Daic (	Jiig	,11141 1 11	ica (wiwi	DD/1111)	0.	. Illuividuai 0	ı John/G	roup rining	(Check Appl	neadle Line)	
BOSTON, N	MA 02110											_2	X Form filed by					
(	City) (Sta	ate) (Zip)	)										Form filed by	More than (	One Reporting I	Person		
		,	Table I - N	on-Dei	rivat	ive Se	curities Ac	equi	red, D	isposed	of, or Be	nefi	icially Owne	d				
1.Title of Security		2. Tran		2A. Deemed Execution		3. Trans. Code						5. Amount of Securities Beneficially Owner Following Reported Transaction(s)			6.	7. Nature		
(Instr. 3)					Execu Date, i		(Instr. 8)			ed of (D) , 4 and 5)			str. 3 and 4)	Transaction	1(S)	Ownership Form:	Beneficial	
									-	1		4				Direct (D) or Indirect	Ownership (Instr. 4)	
										(A) or	<b>.</b>					(I) (Instr.	(Institution)	
Common Stock			11/20	/2025			Code M	V	1,714	t (D) A	Price \$83.85				22,545.667	4) <b>D</b>		
Common Stock			11/20				M		6,230	A	\$133.65				28,775.667	D		
Common Stock			11/20				M		2,434	A	\$44.4				31,209.667	D		
Common Stock			11/20	/2025			M		5,652	A	\$44.4				36,861.667	D		
Common Stock			11/20	/2025			M		9,100	A	\$56.94				45,961.667	D		
Common Stock			11/20	/2025			S		1,714	D	\$190.863 <sup>(1)</sup>	<u>)</u>			44,247.667	D		
Common Stock			11/20	/2025			S		13,339	D	\$192.533 <sup>(2)</sup>	<u>)</u>			30,908.667	D		
Common Stock			11/20	/2025			S		977	D	\$193.233 <sup>(3)</sup>	)			29,931.667	D		
Common Stock			11/20	/2025			S		9,100	D	\$194.3				20,831.667	D		
	Tab	ole II - Deri	vative Sec	urities	Bene	eficiall	y Owned	(e.g.	., puts,	calls, v	varrants,	opt	tions, conver	tible secu	urities)			
Title of Derivate Security	2. Conversion	3A. Deemed Execution	4. Trans Code		5. Num Derivat	iber of tive Securities		Date Exe			itle and Amount of urities Underlying			<ol><li>Number of derivative</li></ol>	10.	<ol><li>Nature of Indirect</li></ol>		
(Instr. 3)	or Exercise	Date	Date, if any	(Instr. 8)	8) Acquire Dispose		ed (A) or	and	т Ехриан	on Date	Derivative	e Sec	curity	Security	Securities	Form of	Beneficial	
	Price of Derivative						ed of (D) 3, 4 and 5)				(Instr. 3 ar	nd 4)	)	(Instr. 5)	Beneficially Owned		Ownership (Instr. 4)	
	Security					`	<u> </u>	-				_	Amount or		Following	Direct (D) or Indirect		
								Dat	te ercisable	Expiration Date	n Title	N	Number of		Reported Transaction(s)	(I) (Instr.		
G. 10 :				Code	V	(A)	(D)	2			-	+	Shares		(Instr. 4)	4)		
Stock Option (Right to Buy)	\$83.85	11/20/2025		M			1,714		(4)	6/4/2030	Stock		1,714	\$0	0	D		
Stock Option (Right to Buy)	\$133.65	11/20/2025		M			6,230		(5)	9/13/203	Stock		6,230	\$0	0	D		
Stock Option (Right to Buy)	\$44.4	11/20/2025		M			2,434	1/1	12/2023	1/12/203	3 Common Stock	n	2,434	\$0	0	D		
Stock Option (Right to Buy)	\$44.4	11/20/2025		M			5,652		<u>(6)</u>	1/12/203	3 Common Stock	n	5,652	\$0	2,347	D		
Stock Option (Right to Buy)	\$56.94	11/20/2025		M			9,100		<u>(7)</u>	7/29/203	4 Common Stock	n	9,100	\$0	19,717	D		

- (1) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from \$190.720 to \$191.540. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- (2) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from \$192.003 to \$193.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- (3) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from \$193.010 to \$193.960. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- (4) This option was fully vested as of January 1, 2024.
- (5) This option was fully vested as of September 9, 2024.
- (6) The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.
- (7) The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date.

#### Remarks:

The transactions reported in this Form 4 were effected for estate planning purposes.

#### Reporting Owners

reporting owners								
Describes Occurs Nieus / Adduses	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Nemiroff Alex								
C/O PRAXIS PRECISION MEDICINES, INC.			Cananal Cauncel and Securitary					
99 HIGH STREET, 30TH FLOOR			General Counsel and Secretary					
BOSTON, MA 02110								

#### **Signatures**

/s/ Alex Nemiroff 11/21/2025

\*\*Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.